ADPT logo

Adaptive Biotechnologies Community

NasdaqGS:ADPT Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

ADPT logo
Adaptive Biotechnologies
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 7 Analysts

ClonoSEQ And NovaSeq X Will Transform Clinical Testing Pipelines

Key Takeaways Strategic partnerships and initiatives to raise test prices and efficiency are expected to drive substantial revenue and margin growth. Focused efforts on cost management and achieving EBITDA positivity aim to enhance earnings and financial stability by 2025.
View narrative
US$11.86
FV
12.4% undervalued intrinsic discount
21.27%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
6 days ago author updated this narrative